Cite

HARVARD Citation

    Gerds, A. et al. (2019). Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia research. pp. 38-44. [Online]. 
  
Back to record